알츠하이머병에서 임상약물시험의 최신 동향

키워드

참고문헌 (44)

1. "Social indicators in Korea" (2013)[URL]
2. Rizzi L, "Global epidemiology of dementia:Alzheimer's and vascular types", Biomed Res Int, 2014, pp.908~915 (2014)
3. "Nationalwide study on the prevalence of dementia in Korean elders" (2008)[URL]
4. Nygaard HB, "Current and emerging therapies for Alzheimer's disease", Clin Ther, 35, pp.1480~1489 (2013)
5. Rogers SL, "A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil study group", Neurology, 50, pp.136~145 (1998)
6. Cummings JL, "Alzheimer's disease drug-development pipeline: few candidates, frequent failures", Alzheimers Res Ther, 6, pp.37~ (2014)
7. Jack CR Jr, "An Operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer’s disease", Ann Neurol, 71, pp.765~775 (2012)
8. Sperling RA, "Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease", Alzheimers Dement, 7, pp.280~292 (2011)
9. Albert MS, "The diagnosis of mild cognitive impairment due to Alzheimer's disease:recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease", Alzheimers Dement, 7, pp.270~279 (2011)
10. McKhann GM, "The diagnosis of dementia due to Alzheimer's disease:recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease", Alzheimers Dement, 7, pp.263~269 (2011)
11. Hardy J, "The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics", Science, 297, pp.353~356 (2002)
12. Jack CR Jr, "Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade", Lancet Neurol, 9, pp.119~128 (2010)
13. Cummings JL, "Defining and labeling disease-modifying treatments for Alzheimer’s disease", Alzheimers Dement, 5, pp.406~418 (2009)
14. Vellas B, "Disease-modifying trials in Alzheimer’s disease: a European task force consensus", Lancet Neurol, 6, pp.56~62 (2007)
15. Becker RE, "Increasing the success rate for Alzheimer's disease drug discovery and development", Expert Opin Drug Discov, 7, pp.367~370 (2012)
16. Salloway S, "Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease", N Engl J Med, 370, pp.322~333 (2014)
17. Relkin N, "Clinical trials of intravenous immunoglobulin for Alzheimer's disease", J Clin Immunol, 34(Suppl 1), pp.S74~S79 (2014)
18. Doody RS, "Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease", N Engl J Med, 370, pp.311~321 (2014)
19. Mangialasche F, "Alzheimer's disease: clinical trials and drug development", Lancet Neurol, 9, pp.702~716 (2010)
20. Vellas B, "Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU", US, Alzheimers Dement, pp.2013, 9[DOI]
21. Vellas B, "EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study", Curr Alzheimer Res, 8, pp.203~212 (2011)
23. Sabbagh MN, "PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease", Alzheimer Dis Assoc Disord, 25, pp.206~212 (2011)
24. Panza F, "Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease", Expert Rev Neurother, 14, pp.973~986 (2014)
26. Farlow MR, "Long-term treatment with active Aβ immunotherapy with CAD106in mild Alzheimer's disease", Alzheimers Res Ther, 7, pp.23~ (2015)
27. Katsuno M, "Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases", J Neurol Neurosurg Psychiatry, 83, pp.329~335 (2012)
28. Administration US Department of Health and Human Services Food and Drug Administration, "Alzheimer's disease: Developing drugs for the treatment of early stage disease", ~ (2013)
29. Gerald Z, "Alzheimer's disease market: hope deferred", Nat Rev Drug Discov, 12, pp.19~20 (2013)
30. Zhang B, "The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice", J Neurosci, 32, pp.3601~3611 (2012)
31. Ni R, "Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain", J Alzheimers Dis, 33, pp.841~851 (2013)
32. Wilkinson D, "Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial", Lancet Neurol, 13, pp.1092~1099 (2014)
33. Serrano-Pozo A, "Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers", Alzheimer Dis Assoc Disord, 24, pp.220~226 (2010)
34. He P, "Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease", PLoS One, 8, pp.e55091~ (2013)
35. Claxton A, "Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia", J Alzheimers Dis, 44, pp.897~906 (2015)
36. Zhang RY, "A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease", Clin Trials, 8, pp.5~14 (2011)
37. Olanow CW, "A double-blind, delayed-start trial of rasagiline in Parkinson's disease", N Engl J Med, 361, pp.1268~1278 (2009)
38. Moulder KL, "Dominantly Inherited Alzheimer Network: facilitating research and clinical trials", Alzheimers Res Ther, 5, pp.48~54 (2013)
39. Solomon A, "Advances in the prevention of Alzheimer's disease and dementia", J Intern Med, 275, pp.229~250 (2014)
40. Sperling RA, "The A4 study: stopping AD before symptoms begin?", Sci Transl Med, 6, pp.228~233 (2014)
41. Reiman EM, "Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments", J Alzheimers Dis, 26(Suppl 3), pp.321~329 (2011)
42. Kivipelto M, "The finnish geriatric intervention study to prevent cognitive impairment and disability(FINGER): study design and progress", Alzheimers Dement, 9, pp.657~665 (2013)
43. Carrié I, "Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial)", J Nutr Health Aging, 16, pp.355~359 (2012)
44. Richard E, "Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress", Alzheimer Dis Assoc Disord, 23, pp.198~204 (2009)

관련 논문AI추천